Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.